A POSSIBILITY TO USE ANTIARRHYTHMIC MEDICATIONS FROM II CLASS AND MODULATED KINESITHERAPY AS PRIMARY PREVENTION OF ATRIAL FIBRILLATION IN METABOLIC SYNDROME PATIENTS

Abstract

Aim. To evaluate the usage of II class antiarrhythmic drugs and modulated kinesitherapy (MK) as primary prevention of atrial fibrillation (AF) in patients with metabolic syndrome (MS) with revelation of short-term risk for this arrhythmia development.Material and methods. We observed 153 patients with MS at the age 58-75 y. o. without AF in anamnesis, but with short-term risk of its development (2 years after examination), defined via comparative analysis of AF course, induced by transesophageal electrocardiostimulation, in dynamic patients observation. All patients, as primary prevention of AF, used antiarrhythmics of the 2nd class, and in side effects development or in contraindications they underwent MK; polyunsaturated fatty acids also used (PUFA).Results. After inclusion to the study 77 (50,33%) of MS patients used II class drugs additionally to therapy, 42 (27,45%) patients underwent MK, and the rest used PUFA. The best clinical effect was found in II class drugs and MK >63,75% and 74,41%, resp. Efficacy of the therapy in this type of patients highly correlated with the improvement of the left ventricle dysfunction, signal-average electrocardiogram, P-wave dispersion and the decrease of the left atrium volume.Conclusion. If the short-term risk of AF found in MS patients, as primary prevention the method of choice is antiarrhythmic therapy II class drugs and MK.

Keywords

• atrial fibrillation
• primary prevention of arrhythmia.